carnitine has been researched along with Acute Lymphoid Leukemia in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The rising hyperbilirubinemia and transaminitis rapidly and permanently reversed using the amino-acid derivative L-carnitine." | 3.83 | L-Carnitine for Treatment of Pegasparaginase-Induced Hepatotoxicity. ( Alshiekh-Nasany, R; Douer, D, 2016) |
| " An adverse effect of asparaginase includes hepatotoxicity, which can lead to severe liver failure and death." | 2.58 | Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature. ( Baker, WJ; Blackman, A; Boutin, A; Forcello, N; Shimanovsky, A, 2018) |
| "Levocarnitine is a mitochondrial co-factor that can potentially ameliorate the mitochondrial toxicity of asparaginase." | 2.58 | Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature. ( Bleyer, A; Burke, MJ; DuVall, A; Flower, A; Hochberg, J; Madiwale, MV; McNeer, JL; Schulte, RR, 2018) |
| "Levocarnitine has been described as potentially beneficial for the treatment or prevention of PEG-ASP-associated hepatotoxicity." | 1.62 | Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. ( Breese, EH; Burke, MJ; Hinson, A; Huynh, V; McNeer, JL; Mixon, BA; Orgel, E; Pierro, J; Rotz, S; Schulte, R, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Schulte, R | 1 |
| Hinson, A | 1 |
| Huynh, V | 1 |
| Breese, EH | 1 |
| Pierro, J | 1 |
| Rotz, S | 1 |
| Mixon, BA | 1 |
| McNeer, JL | 2 |
| Burke, MJ | 2 |
| Orgel, E | 2 |
| Defina, M | 1 |
| Lazzarotto, D | 1 |
| Guolo, F | 1 |
| Minetto, P | 1 |
| Fracchiolla, NS | 1 |
| Giglio, F | 1 |
| Forghieri, F | 1 |
| Vitale, A | 1 |
| Chiaretti, S | 1 |
| Papayannidis, C | 1 |
| Piccini, M | 1 |
| Mulè, A | 1 |
| Bocchia, M | 1 |
| Leoncin, M | 1 |
| Gurrieri, C | 1 |
| Aprile, L | 1 |
| Lunghi, M | 1 |
| Bonifacio, M | 1 |
| Pasciolla, C | 1 |
| Cerrano, M | 1 |
| Fumagalli, M | 1 |
| Foà, R | 1 |
| Candoni, A | 1 |
| Sea, JL | 1 |
| Chen, T | 1 |
| Paszkiewicz, RL | 1 |
| Krall, AS | 1 |
| Oberley, MJ | 1 |
| Stiles, L | 1 |
| Mittelman, SD | 1 |
| Blackman, A | 1 |
| Boutin, A | 1 |
| Shimanovsky, A | 1 |
| Baker, WJ | 1 |
| Forcello, N | 1 |
| Schulte, RR | 1 |
| Madiwale, MV | 1 |
| Flower, A | 1 |
| Hochberg, J | 1 |
| DuVall, A | 1 |
| Bleyer, A | 1 |
| Liu, Y | 1 |
| Janke, LJ | 1 |
| Li, L | 1 |
| Relling, MV | 1 |
| Alshiekh-Nasany, R | 1 |
| Douer, D | 1 |
| Baker, SK | 1 |
| Lipson, DM | 1 |
| Halonen, P | 1 |
| Salo, MK | 1 |
| Schmiegelow, K | 1 |
| Mäkipernaa, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia[NCT05501899] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-03-03 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carnitine and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Asparaginase; Carnitine; Chemical and Drug Induced Liver Injury; Femal | 2018 |
Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carnitine; Chemical and Drug In | 2018 |
7 other studies available for carnitine and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Carnitine; Chemical and Drug Induced Liver I | 2021 |
Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group.
Topics: Adult; Antineoplastic Agents; Asparaginase; Carnitine; Chemical and Drug Induced Liver Injury; Dieta | 2022 |
Levocarnitine does not impair chemotherapy cytotoxicity against acute lymphoblastic leukemia.
Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carnitine; Hum | 2020 |
L-carnitine does not ameliorate asparaginase-associated hepatotoxicity in a C57BL6 mouse model.
Topics: Animals; Antineoplastic Agents; Asparaginase; Carnitine; Chemical and Drug Induced Liver Injury; Dis | 2019 |
L-Carnitine for Treatment of Pegasparaginase-Induced Hepatotoxicity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carnit | 2016 |
Vincristine-induced peripheral neuropathy in a neonate with congenital acute lymphoblastic leukemia.
Topics: Acetylcysteine; Antineoplastic Agents, Phytogenic; Carnitine; Drug Therapy, Combination; Free Radica | 2010 |
Investigation of the mechanisms of therapy-related hypoglycaemia in children with acute lymphoblastic leukaemia.
Topics: Adolescent; Alanine; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Carnitine; Child | 2003 |